暂无分享,去创建一个
Andreas Bender | Jos'e Miguel Hern'andez-Lobato | José Miguel Hernández-Lobato | Gregor N. C. Simm | Sergio Bacallado | Miguel Garc'ia-Orteg'on | Austin J. Tripp | A. Bender | S. Bacallado | G. Simm | Austin Tripp | Miguel Garc'ia-Orteg'on
[1] Reed M. Stein,et al. A practical guide to large-scale docking , 2021, Nature Protocols.
[2] Eva Nittinger,et al. DockStream: a docking wrapper to enhance de novo molecular design , 2021, Journal of Cheminformatics.
[3] Gianni De Fabritiis,et al. Structure based virtual screening: Fast and slow , 2021, WIREs Computational Molecular Science.
[4] Melissa F. Adasme,et al. PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA , 2021, Nucleic Acids Res..
[5] Andreas Bender,et al. Comparison of structure- and ligand-based scoring functions for deep generative models: a GPCR case study , 2021, Journal of Cheminformatics.
[6] Jimeng Sun,et al. Therapeutics Data Commons: Machine Learning Datasets and Tasks for Therapeutics , 2021, ArXiv.
[7] E. Schönbrunn,et al. Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. , 2021, Journal of Medicinal Chemistry.
[8] Gabriel dos Passos Gomes,et al. Beyond generative models: superfast traversal, optimization, novelty, exploration and discovery (STONED) algorithm for molecules using SELFIES , 2020, Chemical science.
[9] David E. Graff,et al. Accelerating high-throughput virtual screening through molecular pool-based active learning , 2020, Chemical science.
[10] Benjamin A. Shoemaker,et al. PubChem in 2021: new data content and improved web interfaces , 2020, Nucleic Acids Res..
[11] A. Bender,et al. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. , 2020, Drug discovery today.
[12] Dongsup Kim,et al. Autonomous molecule generation using reinforcement learning and docking to develop potential novel inhibitors , 2020, Scientific Reports.
[13] Minlie Huang,et al. Reinforced Molecular Optimization with Neighborhood-Controlled Grammars , 2020, NeurIPS.
[14] Al'an Aspuru-Guzik,et al. Bayesian Variational Optimization for Combinatorial Spaces , 2020, ArXiv.
[15] Yurii S Moroz,et al. ZINC20 - A Free Ultralarge-Scale Chemical Database for Ligand Discovery , 2020, J. Chem. Inf. Model..
[16] Alexandros Kalousis,et al. Goal-directed Generation of Discrete Structures with Conditional Generative Models , 2020, NeurIPS.
[17] Jinwoo Shin,et al. Guiding Deep Molecular Optimization with Genetic Exploration , 2020, NeurIPS.
[18] Stanislaw Jastrzebski,et al. We should at least be able to Design Molecules that Dock Well , 2020, ArXiv.
[19] Jos'e Miguel Hern'andez-Lobato,et al. Sample-Efficient Optimization in the Latent Space of Deep Generative Models via Weighted Retraining , 2020, NeurIPS.
[20] Artem Cherkasov,et al. Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery , 2020, ACS central science.
[21] O. Engkvist,et al. REINVENT 2.0 – an AI Tool for De Novo Drug Design , 2020 .
[22] David A. Scott,et al. An open-source drug discovery platform enables ultra-large virtual screens , 2020, Nature.
[23] David E. Shaw,et al. A deep-learning view of chemical space designed to facilitate drug discovery , 2020, J. Chem. Inf. Model..
[24] J. Reymond,et al. SMILES-based deep generative scaffold decorator for de-novo drug design , 2020, Journal of Cheminformatics.
[25] Pascal Friederich,et al. Self-referencing embedded strings (SELFIES): A 100% robust molecular string representation , 2019, Mach. Learn. Sci. Technol..
[26] Krzysztof Rataj,et al. Mol-CycleGAN: a generative model for molecular optimization , 2019, Journal of Cheminformatics.
[27] Alán Aspuru-Guzik,et al. Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models , 2018, Frontiers in Pharmacology.
[28] AkshatKumar Nigam,et al. Curiosity in exploring chemical space: Intrinsic rewards for deep molecular reinforcement learning , 2020, ArXiv.
[29] Kam‐Heung Sze,et al. Machine‐learning scoring functions for structure‐based virtual screening , 2020, WIREs Computational Molecular Science.
[30] Xiaomin Luo,et al. Pushing the boundaries of molecular representation for drug discovery with graph attention mechanism. , 2020, Journal of medicinal chemistry.
[31] Connor W. Coley,et al. Autonomous discovery in the chemical sciences part II: Outlook , 2020, Angewandte Chemie.
[32] T. Jaakkola,et al. Hierarchical Graph-to-Graph Translation for Molecules , 2019 .
[33] Bin Li,et al. Applications of machine learning in drug discovery and development , 2019, Nature Reviews Drug Discovery.
[34] Viktor Hornak,et al. Hidden bias in the DUD-E dataset leads to misleading performance of deep learning in structure-based virtual screening , 2019, PloS one.
[35] Matthias Rarey,et al. In Need of Bias Control: Evaluating Chemical Data for Machine Learning in Structure-Based Virtual Screening , 2019, J. Chem. Inf. Model..
[36] Yurii S. Moroz,et al. Ultra-large library docking for discovering new chemotypes , 2019, Nature.
[37] Yan Li,et al. Comparative Assessment of Scoring Functions: The CASF-2016 Update , 2018, J. Chem. Inf. Model..
[38] Marwin H. S. Segler,et al. GuacaMol: Benchmarking Models for De Novo Molecular Design , 2018, J. Chem. Inf. Model..
[39] Andrew R. Leach,et al. ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..
[40] Jan H. Jensen,et al. A graph-based genetic algorithm and generative model/Monte Carlo tree search for the exploration of chemical space , 2018, Chemical science.
[41] Regina Barzilay,et al. Learning Multimodal Graph-to-Graph Translation for Molecular Optimization , 2018, ICLR.
[42] Niloy Ganguly,et al. NeVAE: A Deep Generative Model for Molecular Graphs , 2018, AAAI.
[43] Andrew Gordon Wilson,et al. GPyTorch: Blackbox Matrix-Matrix Gaussian Process Inference with GPU Acceleration , 2018, NeurIPS.
[44] Jure Leskovec,et al. Graph Convolutional Policy Network for Goal-Directed Molecular Graph Generation , 2018, NeurIPS.
[45] M. Edwards,et al. Lipophilic Efficiency as an Important Metric in Drug Design. , 2018, Journal of medicinal chemistry.
[46] N. Gray,et al. Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.
[47] Anat Levit,et al. STRUCTURE OF THE D2 DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE , 2018, Nature.
[48] Weijun Wang,et al. Protein-Ligand Empirical Interaction Components for Virtual Screening , 2017, J. Chem. Inf. Model..
[49] Lars Carlsson,et al. Erratum to: ExCAPE-DB: an integrated large scale dataset facilitating Big Data analysis in chemogenomics , 2017, Journal of Cheminformatics.
[50] Thomas Blaschke,et al. Molecular de-novo design through deep reinforcement learning , 2017, Journal of Cheminformatics.
[51] Samuel S. Schoenholz,et al. Neural Message Passing for Quantum Chemistry , 2017, ICML.
[52] Lars Carlsson,et al. ExCAPE-DB: an integrated large scale dataset facilitating Big Data analysis in chemogenomics , 2017, Journal of Cheminformatics.
[53] Vijay S. Pande,et al. MoleculeNet: a benchmark for molecular machine learning , 2017, Chemical science.
[54] David Ryan Koes,et al. Protein-Ligand Scoring with Convolutional Neural Networks , 2016, Journal of chemical information and modeling.
[55] J. Tuszynski,et al. Software for molecular docking: a review , 2017, Biophysical Reviews.
[56] Tianqi Chen,et al. XGBoost: A Scalable Tree Boosting System , 2016, KDD.
[57] Jack W Scannell,et al. When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis , 2016, PloS one.
[58] R. Roskoski. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.
[59] Nando de Freitas,et al. Taking the Human Out of the Loop: A Review of Bayesian Optimization , 2016, Proceedings of the IEEE.
[60] Sereina Riniker,et al. Better Informed Distance Geometry: Using What We Know To Improve Conformation Generation , 2015, J. Chem. Inf. Model..
[61] Izhar Wallach,et al. AtomNet: A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-based Drug Discovery , 2015, ArXiv.
[62] Antonio Lavecchia,et al. Machine-learning approaches in drug discovery: methods and applications. , 2015, Drug discovery today.
[63] A. Hopkins,et al. The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.
[64] Iskander Yusof,et al. Considering the impact drug-like properties have on the chance of success. , 2013, Drug discovery today.
[65] Daniel Rauh,et al. De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments , 2013, ACS chemical biology.
[66] Zhizhou Fang,et al. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. , 2013, ACS chemical biology.
[67] A. Joerger,et al. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.
[68] I. Ghosh,et al. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. , 2012, Current pharmaceutical design.
[69] Michael M. Mysinger,et al. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.
[70] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[71] G. V. Paolini,et al. Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.
[72] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[73] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[74] Jan H. Jensen,et al. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.
[75] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[76] Andreas Krause,et al. Information-Theoretic Regret Bounds for Gaussian Process Optimization in the Bandit Setting , 2009, IEEE Transactions on Information Theory.
[77] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[78] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[79] Thomas E. Exner,et al. Influence of Protonation, Tautomeric, and Stereoisomeric States on Protein-Ligand Docking Results , 2009, J. Chem. Inf. Model..
[80] Michalis K. Titsias,et al. Variational Learning of Inducing Variables in Sparse Gaussian Processes , 2009, AISTATS.
[81] Carl E. Rasmussen,et al. Gaussian processes for machine learning , 2005, Adaptive computation and machine learning.
[82] Thomas J. Crisman,et al. Which aspects of HTS are empirically correlated with downstream success? , 2008, Current opinion in drug discovery & development.
[83] Gisbert Schneider,et al. Virtual Screening for Bioactive Molecules: Böhm/Virtual , 2008 .
[84] James E. Ferrell,et al. Mechanisms of specificity in protein phosphorylation , 2007, Nature Reviews Molecular Cell Biology.
[85] David G. Lloyd,et al. Unbiasing Scoring Functions: A New Normalization and Rescoring Strategy , 2007, J. Chem. Inf. Model..
[86] J. Newcomb,et al. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties. , 2007, Bioorganic & medicinal chemistry letters.
[87] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.
[88] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[89] Pierre Baldi,et al. Graph kernels for chemical informatics , 2005, Neural Networks.
[90] B. Staels,et al. Therapeutic roles of peroxisome proliferator-activated receptor agonists. , 2005, Diabetes.
[91] R. Glen,et al. Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.
[92] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[93] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[94] D. Ruppert. The Elements of Statistical Learning: Data Mining, Inference, and Prediction , 2004 .
[95] Eric R. Ziegel,et al. The Elements of Statistical Learning , 2003, Technometrics.
[96] J. Friedman. Greedy function approximation: A gradient boosting machine. , 2001 .
[97] Donald R. Jones,et al. Efficient Global Optimization of Expensive Black-Box Functions , 1998, J. Glob. Optim..
[98] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[99] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[100] W. Guida,et al. The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.
[101] Michael I. Jordan,et al. Advances in Neural Information Processing Systems 30 , 1995 .
[102] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .